The GV-backed heart disease treatment developer intends to go public this year having secured $248m in venture funding.
Tenaya Therapeutics, a US-based heart disease treatment developer which counts internet and technology group Alphabet as an investor, has filed for an initial public offering.
The company intends to float on the Nasdaq Stock Market and set a $100m placeholder target for the offering. Morgan Stanley, Cowen, Piper Sandler and Chardan Capital Markets are the underwriters.
Tenaya is developing treatments utilising cellular regeneration, gene therapy and precision medicine for a variety of health conditions affecting the heart. Its treatments…
